Association of Somatic KRAS Variants with Osteolysis in Arteriovenous Malformations

Abstract

Introduction

The genetic study of vascular anomalies provides a better understanding of their etiopathogenesis and allows the use of targeted therapies. Activating KRAS pathogenic variants promote cell proliferation by activating MAPK and PI3K signalling pathways, which have been associated with the pathogenesis of vascular anomalies, especially high-flow ones such as arteriovenous malformations (AVMs). AVMs' genomic landscape is extensive, and a genotype–phenotype correlation has not been shown. In this study, we aimed to prove an association between KRAS gene mutations and the presence of osteolysis in patients with AVMs. Herein, we present a clinical–molecular retrospective study of patients with AVMs, bone involvement, and KRAS pathogenic variants.

Methods

A retrospective review of patients with AVMs and KRAS somatic variants followed by the Vascular Anomalies Unit at our institution was performed. All patients present bone involvement. We analyzed demographics, clinical features (AVMs location, phenotype), treatment received, and response to treatment. Previous imaging studies were used to assess bone involvement. Genetic studies were performed by high-throughput sequencing using a custom-designed panel.

Results

Of the 77 patients with AVMs currently followed in our clinic, 60 (77.9%) had genetic testing, and 19 (31.6%) presented a KRAS somatic activating variant and were therefore included in the study. There were 12 women and 7 men aged 10 to 79 years. When studying radiographies or CT scans, we found that all 19 patients associated osteolysis adjacent to the AVMs. Regarding the KRAS variants, the most frequent one was p.Gly12Asp, followed by p.Gln61His and p.Gly13Arg. Additionally, we reviewed imaging studies from the other 41 patients with AVMs and different pathogenic variants such as MAP2K1, RASA1, and BRAF, and did not find osteolysis.

Conclusion

We have described for the first time the relationship between somatic, activating KRAS pathogenic variants and osteolysis in patients with AVMs. Early detection of these KRAS alterations in this type of patient should lead us to rule out bone involvement. Moreover, identifying these mutations may help guide targeted therapies, potentially preventing the development of osteolysis and improving patient outcomes.

Keywords

arteriovenous malformation - KRAS - osteolysis

Publikationsverlauf

Eingereicht: 22. August 2024

Angenommen: 15. Februar 2025

Artikel online veröffentlicht:
29. März 2025

• References

• 1 The International Society for the Study of Vascular Anomalies. Classification. Accessed on November 15, 2023 at: https://www.issva.org/classification
• 2 Huang L, Guo Z, Wang F, Fu L. KRAS mutation: from undruggable to druggable in cancer. Signal Transduct Target Ther 2021; 6 (01) 386
• 3 Ersahin T, Tuncbag N, Cetin-Atalay R. The PI3K/AKT/mTOR interactive pathway. Mol Biosyst 2015; 11 (07) 1946-1954
• 4 Nguyen HL, Boon LM, Vikkula M. Genetics of vascular anomalies. Semin Pediatr Surg 2020; 29 (05) 150967
• 5 Schimmel K, Ali MK, Tan SY. et al. Arteriovenous malformations-current understanding of the pathogenesis with implications for treatment. Int J Mol Sci 2021; 22 (16) 9037
• 6 El Sissy FN, Wassef M, Faucon B. et al. Somatic mutational landscape of extracranial arteriovenous malformations and phenotypic correlations. J Eur Acad Dermatol Venereol 2022; 36 (06) 905-912
• 7 Boyd JB, Mulliken JB, Kaban LB, Upton III J, Murray JE. Skeletal changes associated with vascular malformations. Plast Reconstr Surg 1984; 74 (06) 789-797
• 8 Breugem CC, Maas M, Breugem SJ, Schaap GR, van der Horst CM. Vascular malformations of the lower limb with osseous involvement. J Bone Joint Surg Br 2003; 85 (03) 399-405
• 9 Nikolaev SI, Vetiska S, Bonilla X. et al. Somatic activating KRAS mutations in arteriovenous malformations of the brain. N Engl J Med 2018; 378 (03) 250-261
• 10 Lacasta-Plasin C, Martinez-Glez V, Rodriguez-Laguna L. et al. KRAS mutation identified in a patient with melorheostosis and extended lymphangiomatosis treated with sirolimus and trametinib. Clin Genet 2021; 100 (04) 484-485
• 11 Nozawa A, Ozeki M, Niihori T, Suzui N, Miyazaki T, Aoki Y. A somatic activating KRAS variant identified in an affected lesion of a patient with Gorham-Stout disease. J Hum Genet 2020; 65 (11) 995-1001
• 12 Solorzano E, Alejo AL, Ball HC. et al. Osteopathy in complex lymphatic anomalies. Int J Mol Sci 2022; 23 (15) 8258
• 13 Rodriguez-Laguna L, Ibañez K, Gordo G. et al. CLAPO syndrome: identification of somatic activating PIK3CA mutations and delineation of the natural history and phenotype. Genet Med 2018; 20 (08) 882-889
• 14 Triana Junco P, Rodríguez-Laguna L, Martínez-González V, López-Gutiérrez JC. Correlación clínica-genértica en las malformaciones arteriovenosas. Clinicalgenetic correlation in arteriovenous malformations. Paper presented at:13th reunion of the Spanish Society of Vascular Anomalies (SEAV); 22–23 October, 2021.
• 15 Pampín Martínez MM, Rodríguez-Laguna L, Gómez García E, Cebrián Carretero JL, González Otero T, López Gutiérrez JC. Genetic profile of arteriovenous anomalies of the head and neck: Implications in progression and therapeutic approaches. J Pediatr Surg 2023; 58 (10) 2043-2049
• 16 Dellinger MT, Garg N, Olsen BR. Viewpoints on vessels and vanishing bones in Gorham-Stout disease. Bone 2014; 63: 47-52
• 17 Germans MR, Sun W, Sebök M, Keller A, Regli L. Molecular signature of brain arteriovenous malformation hemorrhage: a systematic review. World Neurosurg 2022; 157: 143-151
• 18 Homayun-Sepehr N, McCarter AL, Helaers R. et al. KRAS-driven model of Gorham-Stout disease effectively treated with trametinib. JCI Insight 2021; 6 (15) e149831
• 19 Nguyen HL, Boon LM, Vikkula M. Trametinib as a promising therapeutic option in alleviating vascular defects in an endothelial KRAS-induced mouse model. Hum Mol Genet 2023; 32 (02) 276-289
• 20 Hong DS, Fakih MG, Strickler JH. et al. KRAS G12C inhibition with sotorasib in advanced solid tumors. N Engl J Med 2020; 383 (13) 1207-1217
• 21 Nakajima EC, Drezner N, Li X. et al. FDA Approval Summary: Sotorasib for KRAS G12C-mutated metastatic NSCLC. Clin Cancer Res 2022; 28 (08) 1482-1486